Therapies to prevent severe neonatal unconjugated hyperbilirubinemia and kernicterus are phototherapy and, in unresponsive cases, exchange transfusion, which has significant morbidity and mortality risks. Neurotoxicity is caused by the fraction of unconjugated bilirubin not bound to albumin (free bilirubin, Bf). Human serum albumin (HSA) administration was suggested to increase plasma bilirubin-binding capacity. However, its clinical use is infrequent due to difficulties to address its potential preventive and curative benefits, and to the absence of reliable markers to monitor bilirubin neurotoxicity risk. We used a genetic mouse model of unconjugated hyperbilirubinemia showing severe neurological impairment and neonatal lethality. We treated mutant pups with repeated HSA administration since birth, without phototherapy application. Daily intraperitoneal HSA administration completely rescued neurological damage and lethality, depending on dosage and administration frequency. Albumin infusion increased plasma bilirubin-binding capacity, mobilizing bilirubin from tissues to plasma. This resulted in reduced plasma Bf, forebrain and cerebellum bilirubin levels. We showed that, in our experimental model, Bf is the best marker to determine the risk of developing neurological damage. These results support the potential use of albumin administration in severe acute hyperbilirubinemia conditions to prevent or treat bilirubin neurotoxicity in situations in which exchange transfusion may be required.

Institute of Medical Biochemistry and Laboratory Diagnostics 1st Faculty of Medicine Charles University Prague U Nemocnice 2 Prague 120 00 Czech Republic

International Centre for Genetic Engineering and Biotechnology Padriciano 99 34149 Trieste Italy

Pediatric Gastroenterology and Hepatology Department of Pediatrics Center for Liver Digestive and Metabolic Diseases University of Groningen Beatrix Children's Hospital University Medical Center Groningen Hanzeplein 1 9713 GZ Groningen The Netherlands

Zobrazit více v PubMed

Johnson L. H., Bhutani V. K. & Brown A. K. System-based approach to management of neonatal jaundice and prevention of kernicterus. The Journal of pediatrics 140, 396–403, 10.1067/mpd.2002.123098 (2002). PubMed DOI

American_Academy_of_Pediatrics. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 114, 297–316 (2004). PubMed

Watchko J. F. & Tiribelli C. Bilirubin-induced neurologic damage–mechanisms and management approaches. The New England journal of medicine 369, 2021–2030, 10.1056/NEJMra1308124 (2013). PubMed DOI

Burgos A. E., Flaherman V. J. & Newman T. B. Screening and follow-up for neonatal hyperbilirubinemia: a review. Clinical pediatrics 51, 7–16, 10.1177/0009922811398964 (2012). PubMed DOI

Kaplan M., Bromiker R. & Hammerman C. Severe neonatal hyperbilirubinemia and kernicterus: are these still problems in the third millennium? Neonatology 100, 354–362, 10.1159/000330055 (2011). PubMed DOI

Morioka I. PubMed DOI

Gamaleldin R. PubMed DOI PMC

Iskander I. PubMed DOI PMC

Owa J. A. & Ogunlesi T. A. Why we are still doing so many exchange blood transfusion for neonatal jaundice in Nigeria. World journal of pediatrics: WJP 5, 51–55, 10.1007/s12519-009-0009-2 (2009). PubMed DOI

Slusher T. M., Zipursky A. & Bhutani V. K. A global need for affordable neonatal jaundice technologies. Seminars in perinatology 35, 185–191, 10.1053/j.semperi.2011.02.014 (2011). PubMed DOI

English M. PubMed

Ezeaka V. C., Ekure E. N., Iroha E. O. & Egri-Okwaji M. T. Outcome of low birth weight neonates in a tertiary health care centre in Lagos, Nigeria. African journal of medicine and medical sciences 33, 299–303 (2004). PubMed

Owa J. A. & Osinaike A. I. Neonatal morbidity and mortality in Nigeria. Indian journal of pediatrics 65, 441–449 (1998). PubMed

Bhutani V. K. & Wong R. J. Bilirubin neurotoxicity in preterm infants: risk and prevention. Journal of clinical neonatology 2, 61–69, 10.4103/2249-4847.116402 (2013). PubMed DOI PMC

Ibekwe R. C., Ibekwe M. U. & Muoneke V. U. Outcome of exchange blood transfusions done for neonatal jaundice in abakaliki, South eastern Nigeria. Journal of clinical neonatology 1, 34–37, 10.4103/2249-4847.92239 (2012). PubMed DOI PMC

Hosseinpour Sakha S. & Gharehbaghi M. M. Exchange transfusion in severe hyperbilirubinemia: an experience in northwest Iran. The Turkish journal of pediatrics 52, 367–371 (2010). PubMed

Jackson J. C. Adverse events associated with exchange transfusion in healthy and ill newborns. Pediatrics 99, E7 (1997). PubMed

Keenan W. J., Novak K. K., Sutherland J. M., Bryla D. A. & Fetterly K. L. Morbidity and mortality associated with exchange transfusion. Pediatrics 75, 417–421 (1985). PubMed

Sa C. A. M., Santos M. C. P., de Carvalho M. & Moreira M. E. L. Adverse events related to exchange transfusion in newborn infants with hemolytic disease: ten years of experience. Rev Paul Pediatr 27, 168–172 (2009).

Davutoglu M., Garipardic M., Guler E., Karabiber H. & Erhan D. The etiology of severe neonatal hyperbilirubinemia and complications of exchange transfusion. The Turkish journal of pediatrics 52, 163–166 (2010). PubMed

Ostrow J. D., Mukerjee P. & Tiribelli C. Structure and binding of unconjugated bilirubin: relevance for physiological and pathophysiological function. J Lipid Res 35, 1715–1737 (1994). PubMed

Ostrow J. D. & Schmid R. The Protein-Binding of C14-Bilirubin in Human and Murine Serum. The Journal of clinical investigation 42, 1286–1299, 10.1172/JCI104813 (1963). PubMed DOI PMC

Brodersen R. Bilirubin. Solubility and interaction with albumin and phospholipid. The Journal of biological chemistry 254, 2364–2369 (1979). PubMed

Ostrow J. D., Pascolo L., Brites D. & Tiribelli C. Molecular basis of bilirubin-induced neurotoxicity. Trends in molecular medicine 10, 65–70, 10.1016/j.molmed.2003.12.003 (2004). PubMed DOI

Ahlfors C. E., Amin S. B. & Parker A. E. Unbound bilirubin predicts abnormal automated auditory brainstem response in a diverse newborn population. Journal of perinatology: official journal of the California Perinatal Association 29, 305–309, 10.1038/jp.2008.199 (2009). PubMed DOI PMC

Comley A. & Wood B. Albumin administration in exchange transfusion for hyperbilirubinaemia. Archives of disease in childhood 43, 151–154 (1968). PubMed PMC

Ebbesen F. & Brodersen R. Comparison between two preparations of human serum albumin in treatment of neonatal hyperbilirubinaemia. Acta paediatrica Scandinavica 71, 85–90 (1982). PubMed

Hosono S. PubMed

Odell G. B., Cohen S. N. & Gordes E. H. Administration of albumin in the management of hyperbilirubinemia by exchange transfusions. Pediatrics 30, 613–621 (1962). PubMed

Shahian M. & Moslehi M. A. Effect of albumin administration prior to exchange transfusion in term neonates with hyperbilirubinemia–a randomized controlled trial. Indian pediatrics 47, 241–244 (2010). PubMed

Tsao Y. C. & Yu V. Y. Albumin in management of neonatal hyperbilirubinaemia. Archives of disease in childhood 47, 250–256 (1972). PubMed PMC

Wood B., Comley A. & Sherwell J. Effect of additional albumin administration during exchange transfusion on plasma albumin-binding capacity. Archives of disease in childhood 45, 59–62 (1970). PubMed PMC

Cuperus F. J. PubMed DOI

Schreuder A. B. PubMed DOI

Rice A. C. & Shapiro S. M. A new animal model of hemolytic hyperbilirubinemia-induced bilirubin encephalopathy (kernicterus). Pediatric research 64, 265–269 (2008). PubMed

Bortolussi G. PubMed DOI PMC

Bortolussi G. PubMed DOI PMC

Fanali G. PubMed DOI

Bennhold H. & Kallee E. Comparative studies on the half-life of I 131-labeled albumins and nonradioactive human serum albumin in a case of analbuminemia. The Journal of clinical investigation 38, 863–872, 10.1172/JCI103868 (1959). PubMed DOI PMC

Greissman A., Silver P., Nimkoff L. & Sagy M. Albumin bolus administration versus continuous infusion in critically ill hypoalbuminemic pediatric patients. Intensive care medicine 22, 495–499 (1996). PubMed

Chaudhury C. PubMed PMC

Andersen J. T. PubMed DOI PMC

Andersen J. T., Daba M. B., Berntzen G., Michaelsen T. E. & Sandlie I. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. The Journal of biological chemistry 285, 4826–4836, 10.1074/jbc.M109.081828 (2010). PubMed DOI PMC

Caldera R. PubMed

Morris B. H. PubMed DOI PMC

Ahlfors C. E. & Parker A. E. Unbound bilirubin concentration is associated with abnormal automated auditory brainstem response for jaundiced newborns. Pediatrics 121, 976–978, 10.1542/peds.2007-2297 (2008). PubMed DOI

Ahlfors C. E. Criteria for exchange transfusion in jaundiced newborns. Pediatrics 93, 488–494 (1994). PubMed

Hulzebos C. V. PubMed DOI PMC

Lee Y. K., Daito Y., Katayama Y., Minami H. & Negishi H. The significance of measurement of serum unbound bilirubin concentrations in high-risk infants. Pediatrics international: official journal of the Japan Pediatric Society 51, 795–799, 10.1111/j.1442-200X.2009.02878.x (2009). PubMed DOI

Nakamura H., Yonetani M., Uetani Y., Funato M. & Lee Y. Determination of serum unbound bilirubin for prediction of kernicterus in low birthweight infants. Acta paediatrica Japonica; Overseas edition 34, 642–647 (1992). PubMed

Morioka I. PubMed DOI

Oh W. PubMed DOI PMC

Bortolussi G. PubMed DOI PMC

Ahlfors C. E., Marshall G. D., Wolcott D. K., Olson D. C. & Van Overmeire B. Measurement of unbound bilirubin by the peroxidase test using Zone Fluidics. Clinica chimica acta; international journal of clinical chemistry 365, 78–85, 10.1016/j.cca.2005.07.030 (2006). PubMed DOI

Zelenka J. PubMed DOI

Bilirubin Photoisomers in Neonatal Jaundice

Diagnostic methods for neonatal hyperbilirubinemia: benefits, limitations, requirements, and novel developments

Potential of therapeutic bile acids in the treatment of neonatal Hyperbilirubinemia

Inflammatory signature of cerebellar neurodegeneration during neonatal hyperbilirubinemia in Ugt1 -/- mouse model